{"id":3095,"date":"2010-09-08T14:54:01","date_gmt":"2010-09-08T18:54:01","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=3095"},"modified":"2011-07-19T17:44:50","modified_gmt":"2011-07-19T21:44:50","slug":"new-therapy-for-a-rare-syndrome","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/09\/08\/new-therapy-for-a-rare-syndrome\/","title":{"rendered":"New Therapy for a Rare Syndrome"},"content":{"rendered":"<p>A team of French and Belgian investigators have found a promising new treatment for a rare inherited disorder that often leads to vascular dissection or rupture. In <a href=\"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(10)60960-9\/fulltext?_eventId=login\">a report published online in the <em>Lancet<\/em><\/a>, Kim-Thanh Ong and colleagues compared the effect of celiprolol, a beta-blocker with beta-2 agonist properties, with placebo in 53 patients with Ehlers-Danlos syndrome. After 47 months of follow-up, the trial was stopped early when the investigators observed a significant reduction in ruptures or dissections in the celiprolol group compared with the placebo group (5 vs. 14).<\/p>\n<p>In <a href=\"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(10)61155-5\/fulltext\">an accompanying editorial<\/a>, Benjamin Brooke writes that the study &#8220;represents a substantial breakthrough in the evidence-based management of the syndrome. Celiprolol is an inexpensive well-tolerated drug available to treat patients with vascular Ehlers-Danlos syndrome worldwide.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A team of French and Belgian investigators have found a promising new treatment for a rare inherited disorder that often leads to vascular dissection or rupture. In a report published online in the Lancet, Kim-Thanh Ong and colleagues compared the effect of celiprolol, a beta-blocker with beta-2 agonist properties, with placebo in 53 patients with [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,7],"tags":[376,375,377],"class_list":["post-3095","post","type-post","status-publish","format-standard","hentry","category-general","category-prevention","tag-beta-blocker","tag-celiprolol","tag-ehlers-danlos-syndrome"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=3095"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3095\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=3095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=3095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=3095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}